Filing Flows › Comparisons › SPRY vs VTVT
ARS Pharmaceuticals vs vTv Therapeutics: SPRY and VTVT compared
ARS Pharmaceuticals is the larger company: $37.7M of revenue in its latest quarter (Q3 2026) against $36.8M for vTv Therapeutics (Q1 2026). vTv Therapeutics is more profitable, with an operating margin of 63.1% against -90.6%.
Where the money goes: SPRY and VTVT
ARS Pharmaceuticals (SPRY) · Q3 2026
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.
vTv Therapeutics (VTVT) · Q1 2026
vTv Therapeutics, Q1 2026: revenue $36.8M, operating margin 63.1%, net earnings $24.1M, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
| ARS Pharmaceuticals (SPRY) | vTv Therapeutics (VTVT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 2026 |
| Revenue | $37.7M | $36.8M |
| Revenue growth, Y/Y | +16% | — |
| Operating margin | -90.6% | 63.1% |
| Net earnings | −$35.6M | $24.1M |
| Net margin | -94.4% | 65.5% |
| Operating cash flow | −$33.7M | $9.2M |
Where the revenue comes from
ARS Pharmaceuticals
- Product: $33.4M (89%)
- Revenue Under Supply Agreements: $2.6M (7%)
- Revenue Under Collaboration Agreements: $1.7M (4%)
Questions
Which is bigger, ARS Pharmaceuticals or vTv Therapeutics?
ARS Pharmaceuticals is the larger company: $37.7M of revenue in its latest quarter (Q3 2026) against $36.8M for vTv Therapeutics (Q1 2026).
Is ARS Pharmaceuticals or vTv Therapeutics growing faster?
vTv Therapeutics is more profitable, with an operating margin of 63.1% against -90.6%.
More: ARS Pharmaceuticals earnings · how ARS Pharmaceuticals makes money · vTv Therapeutics earnings · how vTv Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed May 13, 2026). Fiscal quarters can end on different dates. Not investment advice.